Neovasc’s Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference
- Monday, September 30, 2019, 8:02
- Business
- Add a comment
NASDAQ, TSX: NVCN VANCOUVER, Sept. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the…
About the Author
adminasapcorp has written 38936 stories on this site.